Artificial Intelligence & Smart Wearable Technologies for Early Detection

Status Not yet recruiting

Clinical Trial Summary

Heart failure is the major pandemic of the 21st century. The number of patients and of Heart Failure-related deaths is progressively increasing. This means a devastating economic and health organization burden. In fact, chronic heart failure patients are at high risk of death, and the course of the disease is often insidious and uncertain with a progressive deterioration requiring the need for repeated and successive hospitalizations with an ominous prognosis: with each admission for acute heart failure there is a short-term improvement, a phase characterized by a degree of stability, and then a worsening phase follows until a new need for a new hospitalization. Moreover, with each subsequent hospitalization, myocardial function progressively declines, gradually worsening the patient's quality of life until the fatal event. For these reasons, one of the major unmet needs is the identification of patients with a negative trajectory of Heart Failure. Accordingly, early identification of Heart Failure worsening is mandatory to improve patient condition and reduce Heart Failure costs, which are mainly associated with hospitalizations. Our main goal through this project is to create clinical tool for detection of early signs of chronic heart failure (CHF) worsening that will allow timely therapeutic intervention. This timely manner intervention can lead to a much better outcome for the patient, possibly reducing the need for hospitalization or lower the number of hospitalization days. The aim of this project is to develop clinical decision tool based on artificial intelligence (AI) algorithms to early detect the signs of exacerbation of chronic heart failure and predict the risk of its progression, by integrating high quality medical data obtained through a wearable device (L.I.F.E. Italia Srl's "wearable clinic" - a vest with accessories, which is a TRL 9 medical grade sensorized garment, already available on the market). Specifically, the focus will be on the early detection of CHF worsening in patients who have already been diagnosed with CHF.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05591443
Study type	Observational
Source	Centro Cardiologico Monzino
Contact	Piergiuseppe Agostoni, Prof
Phone	0258002010
Email	piergiuseppe.agostoni@ccfm.it
Status	Not yet recruiting
Phase
Start date	May 2023
Completion date	May 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03727646` - Nicotinamide Riboside in LVAD Recipients	Early Phase 1
Withdrawn	`NCT03519477` - Comprehensive Medication Monitoring on Heart Failure Patient Outcomes	N/A
Recruiting	`NCT05596760` - Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers	N/A
Recruiting	`NCT05227872` - PVF in Decongestion of Heart Failure
Recruiting	`NCT05543720` - Evaluation of Nurse-led Integrated Care of Complex Patients Facilitated By Telemonitoring: The SMaRT Study	N/A
Completed	`NCT04572425` - Virtual Reality for Pain Management in Advanced Heart Failure	N/A
Recruiting	`NCT03202329` - Evaluation of Post-operative, Nurse-based Heart Failure Care in Non-cardiac Surgery	N/A
Recruiting	`NCT03830957` - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker	N/A
Recruiting	`NCT02672618` - Clinical Research to Explore Manifestations of Heart Failure Using Infrared Thermal Imaging Technology	N/A
Recruiting	`NCT04179643` - NAN-101 in Patients With Class III Heart Failure	Phase 1
Completed	`NCT04129658` - Heart Failure in Southern Sweden
Completed	`NCT03387813` - Hemodynamic-GUIDEd Management of Heart Failure	N/A
Completed	`NCT04628325` - Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)	Phase 3
Completed	`NCT03187470` - Left Ventricular Dyssynchrony in Multipole Pacing	N/A
Completed	`NCT03385837` - Activity Level and Barriers to Participate of Cardiac Rehabilitation in Advanced Heart Failure Patients
Completed	`NCT04281849` - Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program	N/A
Not yet recruiting	`NCT04403659` - Telemonitoring of Patients Admitted in Hospital at Home With Acute Decompensated Heart Failure - Pilot Study	N/A
Terminated	`NCT04142788` - RELieving Increasing oEdema Due to Heart Failure	Phase 4
Active, not recruiting	`NCT04283994` - Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)	N/A
Completed	`NCT03722069` - Dietary Sodium Intake in Acute Heart Failure	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Artificial Intelligence and Smart Wearable Technologies for Early Detection of Acute Heart Failure — weHeartClinic

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms